Full text is available at the source.
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is a major global chronic liver disease without approved pharmacotherapy.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may provide metabolic benefits.
- The efficacy of GLP-1 RAs on histological endpoints in MASH is not yet established.
- There is a need for definitive synthesis of data regarding GLP-1 RAs in MASH treatment.
Simplified